Overview
The first GLP-1 agonist ever approved, and a genuinely strange origin story: it is a near-copy of a peptide in Gila monster saliva that happens to resist the enzyme that destroys human GLP-1 within minutes. Every drug in this class descends from that observation.
FDA ApprovedFDA-approved for type 2 diabetes (2005). Several formulations have since been discontinued commercially.
| Regulatory status | FDA-approved for type 2 diabetes (2005). Several formulations have since been discontinued commercially. |
|---|---|
| Drug class | GLP-1 receptor agonist — synthetic exendin-4, from Gila monster venom |
| Route | Subcutaneous twice daily, or extended-release weekly |
| Half-life | ~2.4 hours (immediate release) |
| Evidence rating |
5/5 Very strong
Evidence rating 5 out of 5: Very strong
Multiple phase 3 randomized trials plus regulatory approval in a major market. |
| Studied in | AMIGO trials in type 2 diabetes; EXSCEL cardiovascular outcomes trial; DURATION program for the extended-release formulation. |
How it works
Exendin-4 shares roughly 53% sequence identity with human GLP-1 but lacks the DPP-4 cleavage site, so it survives in circulation long enough to be a drug. It produces the same glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying.
Evidence base
Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.
- Two decades of trials and post-marketing data.
- Its cardiovascular trial was neutral, not positive — a useful contrast with semaglutide.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Established glycemic efficacy Strong evidence
HbA1c reductions around 1 percentage point, with weight loss rather than weight gain — the finding that reshaped diabetes care.
-
Cardiovascular safety demonstrated Strong evidence
The EXSCEL trial confirmed cardiovascular safety, though it did not show the superiority later seen with semaglutide and liraglutide.
-
Two decades of safety data Strong evidence
The longest real-world record of any GLP-1 agonist.
-
Proof of concept for the class Strong evidence
Its success created the pathway that led to semaglutide and tirzepatide.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Superseded on efficacy Moderate evidence
Weight loss and glycemic effects are substantially smaller than newer agents. There is little reason to start it today.
-
Twice-daily injection Minor
The immediate-release formulation is the most burdensome regimen in the class.
-
Renal impairment cautions Serious
Not recommended in severe renal impairment; acute kidney injury has been reported, often with dehydration from GI effects.
-
Injection-site nodules with extended release Moderate evidence
The microsphere formulation commonly causes persistent subcutaneous nodules.
-
Antibody formation Moderate evidence
Anti-exenatide antibodies develop in a substantial fraction of users and can reduce efficacy — a problem specific to this non-human sequence.
-
Pancreatitis reports Serious
Class effect; uncommon but serious.
Who should avoid it
- Severe renal impairment (eGFR under 30)
- Prior pancreatitis (relative)
- Pregnancy
- Medullary thyroid carcinoma history (extended-release formulation)
If used under medical supervision, monitor
- HbA1c, weight
- Renal function, particularly during GI illness
- Injection sites
Interactions
Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.
- Warfarin — INR monitoring advised
- Oral antibiotics and contraceptives — take at least 1 hour before exenatide
- Insulin and sulfonylureas — hypoglycemia risk
Regulatory & legal status
Prescription drug; commercial availability of individual formulations has narrowed.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Exenatide
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
- DailyMed — official FDA prescribing information
Related peptides in Metabolic & Weight
Terms used on this page
- Agonist
- An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
- Glucagon-Like Peptide-1 (GLP-1)
- Glucagon-like peptide-1 is an incretin hormone released by intestinal L-cells after a meal that stimulates glucose-dependent insulin secretion and suppresses appetite.
- Glucose-Dependent Insulin Secretion
- Glucose-dependent insulin secretion is beta-cell insulin release that scales with ambient glucose, so incretin amplification fades as concentrations approach the normal range.
- Gastric Emptying
- Gastric emptying is the rate at which stomach contents pass into the duodenum, a major determinant of postprandial glucose and of incretin therapy tolerability.
- DPP-4 Cleavage
- DPP-4 cleavage is the removal of an N-terminal dipeptide by dipeptidyl peptidase-4, the enzymatic step that inactivates incretin hormones within minutes of their release.
- Glucagon
- Glucagon is a 29-amino-acid pancreatic alpha-cell hormone that raises blood glucose by driving hepatic glycogenolysis and gluconeogenesis, and also increases energy expenditure.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.